Nimbus Therapeutics Announced Key Clinical and Business Updates in Oncology Pipeline
Nimbus Therapeutics has made significant strides in its oncology therapeutic pipeline, highlighted by the completion of an Investigational New Drug (IND) application for NDI-219216, a novel Werner syndrome helicase (WRN) inhibitor.
This promising compound is being developed for the treatment of microsatellite instability-high (MSI-H) tumors, and the company plans to initiate its first clinical trial in the first half of 2025.
Dr. Anita Scheuber, M.D., Ph.D., Senior Vice President and Therapeutic Area Head of Oncology, will lead the trial.
Preclinical data for NDI-219216 has been highly promising, demonstrating significant tumor regression and complete responses at low oral doses across various tumor types. Safety studies further indicate a favorable benefit-risk profile as Nimbus prepares to transition the compound into clinical trials. Dr. Scheuber expressed excitement about advancing NDI-219216 into a first-in-human clinical trial later this year.
In addition to NDI-219216, Nimbus recently completed its Phase 1/2 clinical study of NDI-101150, a potent and selective hematopoietic progenitor kinase 1 (HPK1) inhibitor for advanced solid tumors.
Data presented in November 2024 at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting showed monotherapy efficacy and a favorable safety profile, supporting the potential for combination therapy approaches.
The company is actively exploring opportunities to further optimize this program.
Nimbus continues to expand its pipeline beyond oncology, progressing drug discovery efforts in metabolic and autoimmune diseases.
As part of its ongoing collaboration with Eli Lilly and Company, Nimbus is developing novel therapies that activate AMP-activated protein kinase (AMPK) for the treatment of metabolic disorders.
The company has also expanded its pipeline with new undisclosed therapeutic targets, using its innovative computational and structure-based drug design platform.
“Nimbus made great strides in 2024 across oncology, immunology, and metabolism, moving closer to our goal of delivering transformative medicines to patients, Peter’s appointment as President of R&D will play a crucial role in advancing our pipeline, and we are eager to unlock new therapeutic opportunities through our deep computational expertise and strategic partnerships.” – Jeb Keiper, M.S., M.B.A., CEO of Nimbus Therapeutics
Mr. Keiper will provide further updates on the company’s progress, upcoming milestones, and pipeline at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 at 7:30 a.m. PT.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023